Biologic and small-molecule medications in the management of pyoderma gangrenosum

Fatima McKenzie, Devin Cash, Angela Gupta, Laurel W. Cummings, Alex G. Ortega-Loayza

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Pyoderma gangrenosum (PG) is an uncommon inflammatory skin disorder characterized by neutrophil dysfunction. There are currently no FDA-approved drugs for the treatment of this disease, and treatment has typically relied on traditional immunosuppressive medications such as prednisone or cyclosporine. The efficacy of biologics in the treatment of other pro-inflammatory conditions such as psoriasis, rheumatoid arthritis, and inflammatory bowel disease is well-documented in the literature. Therefore, the use of biologic medications for the treatment of rarer inflammatory skin conditions, such as PG, is a compelling topic for investigation. Biologic and small-molecule therapies allow physicians to target specific pro-inflammatory mediators that underlie PG pathogenesis. This review provides an update on the use of biologic and small-molecule medications for the treatment of PG and summarizes the latest data on the clinical efficacy and pharmacology of these treatments.

Original languageEnglish (US)
Pages (from-to)264-276
Number of pages13
JournalJournal of Dermatological Treatment
Issue number3
StatePublished - Apr 3 2019


  • Pyoderma gangrenosum
  • biologics
  • small molecules

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Biologic and small-molecule medications in the management of pyoderma gangrenosum'. Together they form a unique fingerprint.

Cite this